Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Mallinckrodt
AstraZeneca
Harvard Business School
Express Scripts

Last Updated: March 30, 2023

ALECENSA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $100
Remove trial restrictions


When do Alecensa patents expire, and when can generic versions of Alecensa launch?

Alecensa is a drug marketed by Hoffmann-la Roche and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and thirty patent family members in thirty-eight countries.

The generic ingredient in ALECENSA is alectinib hydrochloride. One supplier is listed for this compound. Additional details are available on the alectinib hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Alecensa

Alecensa was eligible for patent challenges on December 11, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 24, 2035. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

Summary for ALECENSA
International Patents:130
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 138
Clinical Trials: 20
Patent Applications: 1,275
Drug Prices: Drug price information for ALECENSA
What excipients (inactive ingredients) are in ALECENSA?ALECENSA excipients list
DailyMed Link:ALECENSA at DailyMed
Drug patent expirations by year for ALECENSA
Drug Prices for ALECENSA

See drug prices for ALECENSA

DrugPatentWatch® Estimated Generic Entry Opportunity Date for ALECENSA
Generic Entry Date for ALECENSA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ALECENSA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of BirminghamPhase 2/Phase 3
Cancer Research UKPhase 2/Phase 3
Royal Marsden NHS Foundation TrustPhase 2/Phase 3

See all ALECENSA clinical trials

Pharmacology for ALECENSA
Drug ClassKinase Inhibitor
Mechanism of ActionKinase Inhibitors
Paragraph IV (Patent) Challenges for ALECENSA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ALECENSA Capsules alectinib hydrochloride 150 mg 208434 1 2019-12-11

US Patents and Regulatory Information for ALECENSA

ALECENSA is protected by five US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ALECENSA is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ALECENSA

Preparation containing tetracyclic compound at high dose
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Preparation containing tetracyclic compound at high dose
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Tetracyclic compound
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Composition comprising tetracyclic compound
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Tetracyclic compound
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting ALECENSA

TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
Exclusivity Expiration: ⤷  Sign Up

FOR TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE, METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST, EXCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ALECENSA

When does loss-of-exclusivity occur for ALECENSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 0187
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 15250574
Estimated Expiration: ⤷  Sign Up

Patent: 20230293
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2016021206
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 46518
Estimated Expiration: ⤷  Sign Up

Patent: 40565
Estimated Expiration: ⤷  Sign Up

China

Patent: 6456651
Estimated Expiration: ⤷  Sign Up

Patent: 3975243
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 35287
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 8363
Estimated Expiration: ⤷  Sign Up

Patent: 3152
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 2015163448
Estimated Expiration: ⤷  Sign Up

Patent: 59712
Estimated Expiration: ⤷  Sign Up

Patent: 29942
Estimated Expiration: ⤷  Sign Up

Patent: 16104762
Estimated Expiration: ⤷  Sign Up

Malaysia

Patent: 9913
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 16013809
Estimated Expiration: ⤷  Sign Up

Russian Federation

Patent: 24056
Estimated Expiration: ⤷  Sign Up

Patent: 16145057
Estimated Expiration: ⤷  Sign Up

Patent: 20119391
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 202009484W
Estimated Expiration: ⤷  Sign Up

Patent: 201607623X
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1606447
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2412321
Estimated Expiration: ⤷  Sign Up

Patent: 2478887
Estimated Expiration: ⤷  Sign Up

Patent: 160146800
Estimated Expiration: ⤷  Sign Up

Patent: 220087583
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 20943
Estimated Expiration: ⤷  Sign Up

Patent: 71839
Estimated Expiration: ⤷  Sign Up

Patent: 1622706
Estimated Expiration: ⤷  Sign Up

Patent: 2114693
Estimated Expiration: ⤷  Sign Up

Patent: 2235088
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ALECENSA around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 3135287 PRÉPARATION CONTENANT UN COMPOSÉ TÉTRACYCLIQUE À HAUTE DOSE (PREPARATION CONTAINING TETRACYCLIC COMPOUND AT HIGH DOSE) ⤷  Sign Up
Singapore 10202009484W PREPARATION CONTAINING TETRACYCLIC COMPOUND AT HIGH DOSE ⤷  Sign Up
China 103052386 Composition containing tetracyclic compound ⤷  Sign Up
Japan 2016104762 4環性化合物を高用量含有する製剤 (FORMULATION CONTAINING HIGH DOSE OF TETRACYCLIC COMPOUND) ⤷  Sign Up
Serbia 58855 TETRACIKLIČNA JEDINJENJA (TETRACYCLIC COMPOUND) ⤷  Sign Up
Brazil PI1011649 compostos tetracíclicos e composição farmacêutica que os compreende ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ALECENSA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2441753 C02441753/01 Switzerland ⤷  Sign Up PRODUCT NAME: ALECTINIBUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65970 26.01.2017
2441753 2017026 Norway ⤷  Sign Up PRODUCT NAME: ALEKTINIB ELLER SALT ELLER SOLVAT; REG. NO/DATE: EU/1/16/1169 20170307
2441753 17C1019 France ⤷  Sign Up PRODUCT NAME: ALECTINIB OU SEL OU SOLVATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/16/1169 20170220
2441753 300876 Netherlands ⤷  Sign Up PRODUCT NAME: ALECTINIB DAN WEL EEN ZOUT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/16/1169/001 20170220
2441753 132017000079367 Italy ⤷  Sign Up PRODUCT NAME: ALECTINIB O UN SUO SALE O SOLVATO(ALECENSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1169, 20170220
2441753 C20170023 00233 Estonia ⤷  Sign Up PRODUCT NAME: ALEKTINIIB;REG NO/DATE: EU/1/16/1169 20.02.2017
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
McKesson
AstraZeneca
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.